Introduction {#sec1-1}
============

Smoking is one of the main leading preventable cause of death and associated with more than five million deaths annually throughout the world. This figure is projected to increase to more than eight million deaths by 2030, of which 80% will occur in developing countries (WHO, 2008). The negative impact of smoking on health care systems and on societies as a whole is substantial, accounting for 1.5-6.8% of national health system budgets and 0.22-0.88% of gross domestic product (GDP) of countries annually (Rezaei et al., 2016). Recognition of the harmful health and financial effects of smoking has led to increased adoption of tobacco control policies in countries around the world, regardless of their social and economic development levels (Goger et al., 2014). The prevalence of smoking in Iran is about 12.5% (23.4% males and 1.4% females), with an average of 13.7 cigarettes per day (Meysamie et al., 2010). Similar to other countries, smoking places a major economic burden on Iran's society (Rezaei et al., 2015; Rezaei et al., 2016). Rezaei and colleagues, for example, showed that smoking is responsible for 4623 cancer deaths, 80 808 years of potential life lost and \$US 83 019 583 cost of productivity losses in Iran (Rezaei et al., 2015). Due to significant differences in the prevalence of smoking, health care systems and socioeconomic context, the costs associated with smoking-related diseases vary across countries. Therefore, it is crucial to conduct country-specific estimates of the costs associated with smoking in order to better understand the economic consequences of smoking. Understanding the economic burden of smoking in Iran can increase public awareness on the extent of the smoking problem which, in turn, can encourage the Iranian government to move forward with the ratification and implementation of the World Health Organization Framework Convention on Tobacco Control (WHO FCTC). In this study, we aimed to provide the first national-level estimate of the economic costs of smoking in Iran. Specifically, we estimated the direct and indirect costs of the three most common smoking-related diseases viz., lung cancer (LC), chronic obstructive pulmonary disease (COPD) and ischaemic heart disease (IHD) from the societal perspective in Iran in 2014. Considering similarities in the tobacco epidemic and social and cultural conditions among the countries in the WHO Eastern Mediterranean Region (EMRO), the findings of our study could provide a valuable evidence for understanding the health and economic benefits of tobacco control programs in this region.

Materials and Methods {#sec1-2}
=====================

A prevalence-based approach was used to estimate the economic costs of the three most common diseases related to smoking: LC, COPD and IHD (Sung et al., 2014). We used the smoking-attributable fraction (SAF), also known as population attributable risk, to determine the proportion of healthcare costs, work loss days and deaths attributable to smoking among adults in Iran. We restricted our analysis to adults aged 35 years and older because it is estimated that there is a latent period of 20 years and more between initial exposure to smoking and occurrence of smoking-related diseases (Sung et al., 2014). We estimated the annual direct and indirect costs of the three smoking-related disease in 2014. Direct costs included hospitalization costs (e.g., doctor visit, surgery, diagnostic tests, medications, hoteling and nursing care costs), outpatient costs and direct non-medical costs (e.g., costs of travel to the health provider, accommodation, food costs, caring for family members such as the elderly or children in the absence of the patient and other utility costs such as telephone bill). Indirect costs included mortality costs measured by the value of life lost prematurely from the smoking-related diseases and morbidity costs (patient time costs) measured by the value of time lost from activities and disability due to smoking-related illness. All the costs were converted to US dollars (US\$) using the average annual 2014 exchange rate (US\$1 = Rial 25 825).

Direct costs and data sources Hospitalization costs {#sec2-1}
---------------------------------------------------

Total smoking-attributable hospitalization (inpatient) costs (TSAH) associated with LC, COPD and IHD were estimated by adopting a methodology recommended by the WHO, as follows (WHO, 2011):
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Where i indicates the type of diseases, j is gender, a is age-groups (35-64 or 65 years and above), C(H) is the average cost of hospitalization and Q(H) indexes the number of hospitalization in one year, P denotes the prevalence of the disease, TP is the total population. SAF represents the smoking-attributable fraction in percentage. As per the WHO recommendation, SAF~ija~ was estimated using the following epidemiological formula (WHO, 2011):
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where P~n~, P~c~ and P~f~ indicate never, current and former smoking prevalence (%), respectively. RR~c~ and RR~f~ are the disease-specific average cost of a one-episode hospitalization for current and former smokers, compared to never smokers, respectively.

To estimate the average cost of hospitalization, C(H), we performed a hospital-based medical record review study. Inpatients care in Iran is delivered in hospitals owned and operated by different health care providers. The Ministry of Health and Medical Education (MOHME) is the main provider of hospital care in Iran. Public hospitals under the MOHME account for 68% of total hospital beds. Private hospitals, social security organization (SSO) hospitals and armed force hospitals account for 12, 9 and 4% of total hospital beds. The rest of hospital beds are owned and operated by independent organizations such as National Iranian Oil Company (NIOC) and non-governmental organizations (NGOs) (Hajizadeh and Nghiem, 2013). We randomly selected 1271 patients, proportionally to the share of each provider from the total hospital beds (i.e., 415 with LC, 429 with IHD and 427 with COPD), who were discharged during the study period. Samples size for each disease was calculated based on the estimated average and standard deviation of hospitalization costs through conducting a pilot study in which medical records of 50 patients were reviewed retrospectively. Data on the smoking status of patients and number of hospitalizations for each patient, Q (H), were obtained by telephone survey.

Outpatient and non-medical costs {#sec2-2}
--------------------------------

Based on a method suggested by the WHO, we used the following formula to estimate the outpatient and non-medical costs associated with the three smoking-related diseases (WHO, 2011):
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where SAC is smoking-attributable costs, i, j, a, P and TP are defined as above, k indicates the type of services (an outpatient or non-medical visit), AC represents the average cost of an outpatient or non-medical care and Q shows the number of outpatient visits. Equation 2 was used to calculate the SAF, whereRR~c~ and RR~f~ index the disease-specific average cost of outpatient visits or non-medical costs for current and former smokers, compared to never smokers, respectively. We conducted a patient survey to estimate the average cost of outpatient care (e.g., drug, exam test, laboratory, magnetic resonance imaging, carpal tunnel syndrome, physician visits) and non-medical costs for each of the three smoking-related diseases. We carried out a survey study among 600 patients (200 patients with each diagnosis) to estimate the cost of outpatient care in the previous month. Samples size for each disease was estimated based on the average and standard deviation of outpatient costs through conducting a pilot study in which 20 patients were interviewed. The estimated monthly outpatient and non-medical costs were multiplied by 12 to reflect the cost for one year. Information on smoking history, work days lost due to receiving outpatient visits, costs of outpatient visits and non-medical costs associated with each outpatient visit were obtained from the patient's questionnaire.

Indirect costs and data sources {#sec2-3}
-------------------------------

Smoking-attributable indirect costs consist of costs associated with morbidity (patient time costs) and premature mortality due to smoking-related diseases. Similar to previous studies (Yang et al., 2011; Anh et al., 2014; Cai et al., 2014; Sung et al., 2014), we used human capital approach to estimate mortality and morbidity costs attributable to smoking.

Morbidity costs attributable to smoking {#sec2-4}
---------------------------------------

We used a methodology recommended by the WHO (WHO, 2011) to calculate indirect costs of morbidity associated with smoking as follows:
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where SAIMB is the smoking-attributable indirect costs of morbidity, i, j, a, P, TP and SAF are defined as above; k indicates types of services (inpatients or outpatient care), AWLD represents the average work-loss days and AERN is average daily earnings. SAF was determined as in Equation 2 with RR~c~ and RR~f~ representing the disease-specific average work-loss days due to outpatient or inpatient care for current and former smokers, compared to never smokers, respectively. The AWDL for inpatient care were taken from medical records. The AWDL for outpatient care was estimated using a self-administrated questionnaire. We used a minimum daily wage approved by the Iranian Ministry of Cooperation, Labor and Social Welfare (IMCLSW) in 2014 as the AERN for the inpatient care. For the outpatient care, the AERN of the patient was estimated by dividing the monthly income of the patient by thirty. The patient time cost was calculated by multiplying the average number of lost days by the average daily income.

Mortality costs attributable to smoking {#sec2-5}
---------------------------------------

As per the WHO recommendation (WHO, 2011), we used the following formula to estimate smoking-attributable indirect mortality costs (SAIMT) for each disease by gender and 5-year age-groups (35-65 years):
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where Tdeath is the total number of deaths, PVLE indicates the present discounted value of lifetime earnings, i, j, a, and SAF are defined as above. The PVLE per death by gender and age groups was estimated using an approach developed by Max and colleagues as follow (Max et al., 2004):
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where PVLE~ag~ is the present discounted value of lifetime earnings for a person who died at the age a and gender g, P~ag~ (n) indicates the probability of survival until the age n for a person of age a and gender g. Y~g~ (n) represents average annual earnings of an employed person of gender g and age n. E~g~(n) is the proportion of the population of gender g and age n who are employed in the labor market. YH~g~(n) indexes the average annual imputed value of household production for a person of gender g and age n. EH~g~(n) represents the proportion of the population of gender g and age n that are housekeepers. P and r denote growth rate of labor productivity (mean economic growth in the past 30 years in Iran = 3%) and appropriate discount rate (3 %), respectively.

The total number of deaths in 5-years in different age groups due to lung cancer for Iran was extracted from the Institute for Health Metrics and Evaluation (IHME) and the Global Burden of Disease Study (GBD). Data on the age- and gender-specific wages for the study period was obtained from the IMCLSW. Further, data on the age and gender-specific employment and housekeeping rates for the study period were drawn from the Iranian Statistical Center and Central Bank of Iran. Since there is no available data on the wages for housekeeping activity in Iran, the minimum daily wage approved by the IMCLSW was used for the females engaged in housekeeping activities. The probability of survival until the age n for a person of age a and gender g was obtained from the WHO data set. We restricted our analysis to individuals aged 65 (retirement age in Iran) and younger when we measured the costs of lost productivity attributable to smoking due to morbidity and premature mortality.

Results {#sec1-3}
=======

[Table 1](#T1){ref-type="table"} reports Prevalence (%) of smoking and smoking attributable fraction for hospitalization costs and outpatient costs (outpatient care and non-medical costs) by disease, gender and age-groups in Iran in 2014. Based on patient's survey, the prevalence of current smoking among patients was 33.9%. The prevalence of former and never smoking were 12% and 54.1%, respectively. Prevalence of smoking was higher among males compared to females (42.8 vs. 15.3 % for current smoking). The smoking-attributable fraction associated with outpatient care and non-medical costs for LC was 12.1 and 14.7%, respectively, whereas the corresponding figures for COPD were 7.8 and 15.8 % and for IHD were 9 and 9.7 %.

###### 

Prevalence (%) of Smoking aAnd Smoking Attributable Fraction for Hospitalization Costs and Outpatient Costs (Outpatient Care and Non-Medical Costs) by Disease, Gender and Age-Groups in Iran in 2014

  Disease                                        Male            Female   
  ---------------------------------------------- ------- ------- -------- ------
  Lung cancer (LC)                                                        
   Current smoking (%)                           57      42      21       20
   Former smoking (%)                            13      15      16       11
   Never smoking (%)                             30      43      63       69
   SAF for hospitalization costs (%)             44.3    42.6    11.5     11.4
   SAF (%) outpatient care costs                 17.26   21.68   5.68     3.86
   (%) direct non-medical costs                  27.07   14.18   9.07     8.27
  Chronic obstructive pulmonary disease (COPD)                            
   Current smoking (%)                           45      38      12       10
   Former smoking (%)                            14      13      9        9
   Never smoking (%)                             40      49      79       81
   SAF for hospitalization costs (%)             29.2    13.6    9.09     10.7
   SAF (%) outpatient care costs                 16.32   5.46    2.91     6.51
   (%) direct non-medical costs                  21.05   24.41   13.06    4.77
  Ischaemic heart disease (IHD)                                           
   Current smoking (%)                           38      27      13       10
   Former smoking (%)                            9       16      7        8
   Never smoking (%)                             54      57      81       82
   SAF for hospitalization costs (%)             13.83   13.82   5.62     6.56
   SAF (%) outpatient care costs                 12.5    16.4    4        3.2
   (%) direct non-medical costs                  18.5    10.9    4.78     4.78

The estimated number of patients who were admitted to hospitals in the entire country due to LC, COPD and IHD in 2014 were 4775,16,236 and 398,807, respectively. Total costs of hospitalization for the three diseases was estimated to be US\$762 558 114, of which US\$688,464 976 was related to IHD, US\$64,559,299 to COPD and US\$9 533 839 to LC. Total smoking-attributable costs of hospitalization for three diseases was estimated to be US\$75,703,330, of which US\$62,094,385 was related to IHD, US\$10 396 701 to COPD and US\$3,212,244 to LC. Generally, smoking was responsible for 9.9% of total cost of hospitalization for these diseases. [Table 2](#T2){ref-type="table"} presents the total number of outpatient visits, total costs of outpatient care and non-medical costs-attributable to smoking in 2014 for the entire country by type of diseases, gender and age-groups. Total costs of outpatient care and non-medical care for the three smoking-related diseases were estimated to be US\$1 627 934 250 and US\$1 448 288 523, correspondingly. Based on the results reported in [Table 4](#T3 T4){ref-type="table"}, 11.5% (US\$186 460 109) of total costs of outpatient care and 10.4 % (US\$150 374 846) of total costs of non-medical care were associated with smoking.

###### 

Estimated Number of Outpatient Visits, Total Outpatient Care and Non-Medical Costs (US\$) Attributable to Smoking By Type of Diseases, Gender and Age-Groups in Iran in 2014

  Disease                                                                         Male          Female                        
  ------------------------------------------------------------------------------- ------------- ------------- --------------- -------------
  Lung cancer (LC)                                                                                                            
   Estimated number of outpatient visits                                          1,377         1,884         773             741
   Costs of outpatient care                                                       1,144,523     1,534,087     630,649         691,411
   Non-medical care costs                                                         949,770       1,331,210     546,192         538,691
   Costs of outpatient care attributable to smoking                               197,549       332,558       35,845          26,676
   Costs of non-medical care attributable to smoking                              188,774       445,913       49,557          44,527
   Total costs of outpatient care associated with LC                              4,000,674                                   
   Total non-medical costs associated with LC                                     3,365,862                                   
   Total costs of outpatient care attributable to smoking associated with LC      592,631                                     
   Total costs of non-medical care attributable to smoking associated with LC     539,992                                     
  Chronic obstructive pulmonary disease (COPD)                                                                                
   Estimated number of outpatient visits                                          56,683        32,126        101,178         25,860
   Costs of outpatient care                                                       37,791,179    18,465,994    54,737,820      14,801,917
   Non-medical care costs                                                         35,974,134    23,093,688    60,590,587      17,450,963
   Costs of outpatient care attributable to smoking                               6,167,520     1,008,244     1,592,871       963,605
   Cost of non-medical care attributable to smoking                               7,554,567     563,4862      7,876,774       832,414
   Total costs of outpatient care associated with COPD                            125,796,910                                 
   Total non-medical costs associated with COPD                                   137,109,375                                 
   Total costs of outpatient care attributable to smoking associated with COPD    9,732,240                                   
   Total costs of non-medical care attributable to smoking associated with COPD   2,189,8614                                  
  Ischaemic heart disease (IHD)                                                                                               
   Estimated number of outpatient visits                                          467,637       88,348        760,523         145,786
   Costs of outpatient care                                                       471,223,946   102,785,231   765,039,710     159,087,775
   Non-medical care costs                                                         438,211,802   83,808,306    666,186,265     119,606,912
   Costs of outpatient care attributable to smoking                               58,902,993    3,060,159     16,891,493      5,090,807
   Costs of non-medical care attributable to smoking                              81,226,362    9,124,968     31,873,010      5,711,899
   Total costs of outpatient care associated with IHD                                                         1,498,136,666   
   Total non-medical costs associated with IHD                                                                1,307,813,286   
   Total costs of outpatient care attributable to smoking associated with IHD                   176,135,237                   
   Total costs of non-medical care attributable to smoking associated with IHD    127,936,240                                 

###### 

Total Deaths, Years of Potential Life Lost and Costs of Mortality (US\$) Due to Smoking by Type of Diseases and Gender in Iran, in 2014

  Disease                                                    Male            Female                     
  ---------------------------------------------------------- --------------- ------------ ------------- ------------
  Lung cancer (LC)                                                                                      
   Number of total death\*                                   1303            1851         525           713
   Smoking-attributable total death                          877             1126         77            127
   Total years of potential life lost                        1,755,745       1,332,743    753,664       544,935
   Smoking-attributable total years of potential life lost   1,179,860       810,307      109,884       96,780
   Total cost of mortality                                   76,219,427      \-           26,126,072    \-
   Smoking-attributable costs of mortality                   51,219,454      \-           3,809,181     \-
   SAF for death, YPPL and costs of mortality                67.3            60.8         14.6          17.8
  Chronic obstructive pulmonary disease (COPD)                                                          
   Number of total death                                     1285            3830         555           2616
   Smoking-attributable total death                          605             1647         75            377
   Total years of potential life lost                        4,428,010       2,435,190    2,615,717     1,712,408
   Smoking-attributable total years of potential life lost   817,359         1,047,132    105,710       246,587
   Total cost of mortality                                   154,687,644     \-           81,692,457    \-
   Smoking-attributable costs of mortality                   72,857,882      \-           11,028,585    \-
   SAF for death, YPPL and costs of mortality                47.1            43           13.5          14.4
  Ischaemic heart disease (IHD)                                                                         
   Number of total death                                     14,704          32,704       6136          24,456
   Smoking-attributable total death                          6190            4742         669           1167
   Total years of potential life lost                        19,970,576      20,988,542   8,656,190     162,90,412
   Smoking-attributable total years of potential life lost   8,407,612       943,525      3,043,339     777,053
   Total cost of mortality                                   1,863,483,338   \-           897,232,720   \-
   Smoking-attributable costs of mortality                   784,526,486     \-           97,798,366    \-
   SAF for death, YPPL and costs of mortality                42.1            14.5         10.9          4.8

Note, Since we do not have available information on the number of deaths associated with the three diseases included in our study for the year 2014, we used number of deaths in 2013 in our calculations.

###### 

Total Economic Burden of Smoking (US\$) by Each Component of Costs and Disease in Iran, in 2014

  Disease                                 Hospitalization Costs   Outpatient Costs   Non-medical Costs   Morbidity Costs   Mortality Costs   Total Costs
  --------------------------------------- ----------------------- ------------------ ------------------- ----------------- ----------------- ---------------
  Lung Cancer                             3,212,248               592,627            539,992             268,891           55,028,635        59,642,401
  Chronic Obstructive Pulmonary Disease   10,396,705              9,732,240          21,898,618          6,418,881         83,886,467        132,332,906
  Ischaemic Heart Disease                 62,094,389              176,135,237        127,936,240         18,039,632        882,324,852       1,266,530,350
  Total                                   75,703,342              186,460,104        150,374,850         24,727,404        1,021,239,954     1,458,505,657
  Percentage of total costs               5.2                     12.8               10.3                1.7               70                100

The estimated total costs of morbidity due to hospitalization and outpatient care for the three diseases were estimated to be US\$58 032 650 and US\$636 455 578, respectively. In LC, total costs of morbidity due to hospitalization and outpatient due to smoking was estimated to be US\$98 892 and US\$176 999, respectively. Whereas the corresponding figures for COPD were US\$2 455,900 and US\$3 962,978 and for IHD were US\$1 502 676 and US\$16 536 956, respectively. The study showed that smoking was responsible for 7% (US\$4 050 467) of total costs of morbidity due to hospitalization and 3.25% (US\$20 676 933) of total costs of morbidity due to receiving outpatient care for the three disease included in the study.

The overall number of deaths from LC, COPD and IHD was estimated to be 90 678 over the study period in Iran and smoking was responsible for approximately 19.5% of these deaths (17, 679 deaths). Moreover, years of potential life lost (YPLL) for three diseases was estimated to be 81,484,132 years and 21.6% of these years (17,585 148 years) was attributable to smoking. Based on 3% discount rate, the overall costs of mortality attributable to smoking was estimated to be US\$ 1,021,239,953 (approximately 32.9% of the overall costs of mortality), including US\$908 603 822 for males (89%) and US\$112 636,132 (11%) for females (see [Table 3](#T3){ref-type="table"}).

[Table 4](#T4){ref-type="table"} displays total direct and indirect costs attributed to smoking for Iran in 2014. The total economic cost of smoking for the three smoking-related diseases was US\$1 458 505 657, including US\$1 045 967 357 (71.7 %) in indirect costs (mortality and morbidity costs) and US\$412 538 296.2 (28.3 %) in direct costs (hospitalization, outpatient and non-medical costs).

Discussion {#sec1-4}
==========

This study is the first attempt to estimate the economic burden of smoking in Iran. The results of our study confirmed that smoking imposes significant health and economic costs on society in Iran. The direct costs of smoking-attributable costs for the three main diseases associated with smoking in Iran (i.e., LC, COPD and IHD) amounted to US\$ 412,538,296 and accounted for 1.6% of Iran's total expenditures on health in 2014. Additionally, smoking led to 17 679 premature deaths corresponding to 17,585,148 YPLLs. It is also responsible for US\$ 1,021,239,955 in indirect costs of lost productivity due to premature deaths and US\$ 24,727,404 in indirect costs of loss-work days due to smoking-related diseases. These costs summed to US\$1,458,505, 657, accounting for 0.26 % of Iran's GDP in 2014.

It should be noted that comparing economic costs of smoking-related diseases in different countries is extremely difficult. This is because income and employment rates among males and females can affect the estimated indirect costs associated with smoking-related diseases in different countries. Differences in health systems, including costs and service delivery, can also explain some of the variations in the estimated costs of smoking-related diseases across countries. However, despite these limitations, our results indicated that the proportion of GDP losses related to the smoking in Iran is comparable to those estimated for Vietnam (0.22%) (Anh et al., 2014), and is less than those reported for Taiwan (0.4 %) (Sung et al., 2014), South Korea (ranging from 0.59 % to 0.78 %) (Kang et al., 2003) and China (0.7 %) (Yang et al. 2011). The lower economic burden of smoking in Iran compared to other Asian countries can partially be explained by lower smoking prevalence in Iran (Meysamie et al., 2010). Moreover, the actual direct costs associated with smoking is higher than what we have reported in our study because our measurement is based on the hospital records that do not contain information on any payments for long-term care and nursing home care. Furthermore, unlike to the previous studies (McGhee et al., 2006; Cai et al., 2014; Sung et al., 2014), we estimated smoking-attributable costs for only three smoking-related diseases among active smokers in Iran, which led to lower economic costs of smoking in Iran compared to other countries.

We found a gender difference in the number of deaths, YPLL and total costs attributable to smoking in Iran. The results revealed that 68% of 17,679 smoking-attributable deaths and 87% of 17,585,148 YPLL caused by smoking were among males. Similarly, 87.2% of total smoking-attributable costs were among males. These results are in consistence with the findings from studies conducted in Germany in 2003 (Neubauer et al., 2006), South Korea in 2003 (Kang et al., 2003) and Taiwan in 2010 (Sung et al., 2014). A study by Neubauer et al., (2006) indicated that smoking was responsible for 13.4% of total deaths in Germany, which 69.3% of these deaths were among males. Another study by Sung et al., (2014) in Taiwan also demonstrated a substantial difference between males and females with respect to smoking-related deaths in Taiwan, 13,744 male deaths compared to 615 female deaths. Yung et al., (2011) showed that the total costs of smoking in China were US\$ 28.9 billion in 2008 and 92% of total smoking-attributable costs was among males. The main reasons for the observed gender differences in smoking-attributable costs can be explained by higher prevalence of smoking, employment rate, and wage rates among males compared to their female counterparts.

The results of our study suggested that total costs of smoking for the three common smoking-related diseases were US\$1,458,505,657. The mortality costs associated with the three diseases is estimated to account for 70% of total costs of smoking and 97.6% of total indirect costs of smoking. Furthermore, the direct costs accounting for 28.3% of total costs of smoking. The costs of premature deaths were reported to be responsible for 76.1%, 91%, 46%, 64% and 50% of the total costs of smoking in China (Yang et al., 2011), Vietnam (Anh et al., 2014), South Korea (Kang et al., 2003), USA (Max et al., 2004), Germany (Neubauer et al., 2006) and Taiwan (Sung et al., 2014), correspondingly. Our findings are comparable to a study by Yang et al., (2011) which demonstrated that the total costs of smoking for Germany to be \$ 28.9 billion; US\$ 6.2 billion (21.5%) in direct costs and US\$ 22.0 billion (76.1%) in indirect mortality costs and US\$ 0.7 billion (2.4%) in indirect morbidity costs.

The actual total direct and indirect costs of smoking in Iran are higher than what we have reported in our study. This is because we only focused on the economic costs of the three main smoking-related diseases in our study and it has been shown that smoking is closely associated with many other diseases such as different type of cancers (e.g., stomach, uterine, cervix, pancreas and kidney and acute myeloid leukemia), pneumonia, abdominal aortic aneurysm, reproductive and erectile as we did not measure the costs associated with all smoking-related diseases, our study underestimated the actual costs of smoking in Iran. In addition, since we did not measure the costs of secondhand smoke exposure on society in Iran, the actual costs of smoking are projected to be higher than what we have reported in this study. In fact, the results of some recent studies (Mchee et al., 2006; Cai et al., 2014; Sung et al., 2014) demonstrated that the costs associated with secondhand smoke exposure contributed significantly to the overall costs of smoking. For example, the costs associated with secondhand smoke represented 23% and 8% of the total costs of smoking in Hong Kong (McGhee et al., 2006) and Taiwan (Sung et al., 2014), respectively. Furthermore, since we used the average income per capita in Iran to estimate the indirect cost of smoking (i.e., GDP per capita for mortality and daily wage rate for morbidity), we underestimated the overall costs of smoking in Iran because a greater proportion of smokers are males who have higher income compared to females. Caveat considered, our study indicated that smoking places a substantial economic burden on Iran's health system and on society as a whole. Therefore, sustained smoking cessation interventions and tobacco control policies are required to reduce the magnitude and extent of smoking-attributable costs in Iran.
